FABP9 Antibody, FITC conjugated
-
中文名称:FABP9兔多克隆抗体, FITC偶联
-
货号:CSB-PA604514HC01HU
-
规格:¥880
-
其他:
产品详情
-
产品名称:Rabbit anti-Homo sapiens (Human) FABP9 Polyclonal antibody
-
Uniprot No.:
-
基因名:FABP9
-
别名:15 kDa perforatorial protein antibody; Fabp9 antibody; FABP9_HUMAN antibody; Fatty acid binding protein 9; testis antibody; Fatty acid-binding protein 9 antibody; PERF antibody; PERF15 antibody; T-FABP antibody; Testis lipid-binding protein antibody; Testis-type fatty acid-binding protein antibody; TLBP antibody
-
宿主:Rabbit
-
反应种属:Human
-
免疫原:Recombinant Human Fatty acid-binding protein 9 protein (1-132AA)
-
免疫原种属:Homo sapiens (Human)
-
标记方式:FITC
-
克隆类型:Polyclonal
-
抗体亚型:IgG
-
纯化方式:Antigen Affinity Purified
-
浓度:It differs from different batches. Please contact us to confirm it.
-
保存缓冲液:Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 -
产品提供形式:Liquid
-
储存条件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
货期:Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途:For Research Use Only. Not for use in diagnostic or therapeutic procedures.
相关产品
靶点详情
-
基因功能参考文献:
- FABP9 is a valuable prognostic marker to predict the outcomes of prostate cancer patients, perhaps by playing an important role in prostate cancer cell invasion. PMID: 27779102
- Serum A-FABP might be a prognostic marker of body weight loss suggesting a preventive therapeutic intervention. PMID: 18803274
- Observational study of gene-disease association. (HuGE Navigator) PMID: 18950845
-
亚细胞定位:Cytoplasm.
-
蛋白家族:Calycin superfamily, Fatty-acid binding protein (FABP) family
-
数据库链接:
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-